Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 2Phase 1/2 1

Status

Completed 9Terminated 3Recruiting 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × poly ICLC × Clear all
NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06343077 2024-04-02

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

Icahn School of Medicine at Mount Sinai

Phase 2 Recruiting
114 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡